Characterizing the Human Airway Immune Response to FluMist Vaccination
Purpose
The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant, volunteers between the ages of 18 and 40. The main purpose of the study is to measure the change in influenza vaccine-specific antibodies in the lower lungs and nose between vaccination and 14 days after participants receive the vaccine. All participants will be randomized to receive one of the two seasonal flu vaccines and will have blood and back of the nose swabs collected throughout the study. Some study participants will choose to undergo optional bronchoscopy procedures and will be included in the part of the study looking at lower lung immune responses.
Conditions
- Healthy Young Adults
- Influenza Vaccines
- Influenza Vaccine Response
Eligibility
- Eligible Ages
- Between 18 Years and 40 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Healthy adults aged 18-40 years - Able to understand and give written informed consent - In stable health, as determined by medical history and targeted physical exam related to the history
Exclusion Criteria
- Prisoners - Anyone unable to provide full written informed consent - Pregnant women and nursing mothers or women who are planning to become pregnant during the study interval - Female subjects who are sexually active with male partners who are not actively on hormonal contraception or who do not have an IUD in place - Vaccination with a seasonal influenza vaccine or documented infection with seasonal influenza in the past 9 months - Receipt of any vaccine in the 28 days prior to the pre-vaccination study visit or planned receipt of any non-study vaccine before completion of study day 28 visit - Current smokers - BMI > 40 - Individuals with an immunocompromising medical condition or who have received systemic immunosuppressants or immune-modifying drugs for > 14 days in total within 6 months prior to screening (for corticosteroids ≥ 10 mg/day of prednisone equivalent for > 14 days total) or is anticipating the need for immunosuppressive treatment at any time during participation in the study - Individuals who currently have symptomatic acute or unstable chronic disease requiring medical or surgical care, to include significant change in therapy or hospitalization, at the discretion of the investigator - History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the study - Have donated blood, blood products, or bone marrow within 30 days before study entry, plan to donate blood at any time during the duration of study participation, or plan to donate blood within 30 days after the last blood draw. - Current ongoing participation in a clinical trial evaluating an investigational agent unless the trial is in follow up only and the last dose of the investigational agent was taken >30 days or >5 half-lives prior to enrollment, whichever is greater. - Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial. For participants willing to undergo bronchoscopy: - Any known chronic pulmonary, cardiovascular, neurologic or hematologic disorder that could, in the opinion of the physician bronchoscopist or the principal investigator, put the subject at unnecessary risk from the sedation and bronchoscopy procedures. These conditions may include, but are not limited to, the following: asthma, COPD, obstructive sleep apnea, pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, heart failure, previous myocardial infarction, hypertrophic cardiomyopathy, supraventricular tachycardia, paraplegia, quadriplegia, epilepsy, sickle cell disease, hemophilia, chronic anemia or active cancer. - Coagulopathy (primary or iatrogenic) which would contraindicate bronchoscopy for participants willing to have those procedures done. Any participant with an INR>1.4, PTT>40 or platelet count <100,000 at study screening will not be eligible for bronchoscopy. - Evidence of significant pulmonary disease on the day of bronchoscopy, including pulse oximetry with oxygen saturation of 92% or less on room air, or infiltrate or pleural effusion on an upright PA and lateral chest x-ray performed on the day of bronchoscopy. - Allergy or contraindication to anesthesia for participants willing to have bronchoscopy done.
Study Design
- Phase
- Phase 4
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental FluMist bronchoscopy group |
Individuals who undergo all bronchoscopy procedures randomized to receive FluMist vaccine |
|
|
Experimental FluMist no bronchoscopy group |
Individuals who do not complete day 14 or day 90 bronchoscopy procedures randomized to receive FluMist vaccine |
|
|
Active Comparator inactivated influenza vaccine bronchoscopy group |
Individuals who undergo all bronchoscopy procedures randomized to receive inactivated influenza vaccine |
|
|
Active Comparator inactivated influenza vaccine no bronchoscopy group |
Individuals who do not complete day 14 or day 90 bronchoscopy procedures randomized to receive inactivated influenza vaccine |
|
Recruiting Locations
Washington University in St. Louis and nearby locations
St Louis 4407066, Missouri 4398678 63110
More Details
- NCT ID
- NCT07177417
- Status
- Recruiting
- Sponsor
- Washington University School of Medicine
Detailed Description
Study Design/Methodology: Prospective randomized controlled trial; Study Duration: 2 years; Number of Subjects: 30; Subject Participation Duration: 4 months; Description of Interventions: Eligible healthy participants who have not received a seasonal influenza vaccine within the past 9 months will complete written informed consent. Enrolled participants will be randomized to receive either an FDA-approved intramuscular seasonal egg-based inactivated influenza vaccine (IIV) (N=15) or the FDA-approved seasonal FluMist intranasal live attenuated influenza vaccine (N=15) on study day 0. Blood samples and nasopharyngeal swabs will be collected at the time of study enrollment (up to 45 days prior to vaccination) and on days 3±1, 7±2, 14±3, 28±5, and 90±14 post-vaccination. Sixteen participants (N=8 in each vaccine group) will be enrolled for optional research bronchoscopy procedures. Research bronchoscopies will include bronchoalveolar lavage (BAL) and endobronchial biopsy (EBBx) sample collection. Research bronchoscopies will be performed prior to vaccination and on study days 14±3 and 90±14. Screening safety laboratory studies and screening chest x-ray imaging will be performed on subjects undergoing research bronchoscopies.